Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | RPA1 | P27694 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29698008 | 1.00 | MAPT (0.61) | MAPTMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL14291954 | 0.86 | MAPT (0.68) | MAPTMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL13870883 | 0.82 | MEN1 (0.81) | MAPTMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL16386084 | 0.77 | NPC1 (0.54) | MAPTMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL6403077 | 0.77 | KMT2A (0.81) | MAPTMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL27180424 | 0.76 | IDH1 (0.62) | MAPTMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL17179708 | 0.76 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13870881 | 0.76 | MEN1 (0.86) | MAPTMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL15919822 | 0.75 | MEN1 (0.78) | MAPTMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL13870884 | 0.74 | MEN1 (0.88) | MAPTMEN1KMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2823816-A1 | Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases | Tragex Pharma (FR) | 2015-01-14 | — | — | EP | claimed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20220307021-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | UNIVERSITÉ PARIS CITÉ (FR) | 2022-09-29 | — | — | US | disclosed |
| WO-2021105368-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105368-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-03 | — | — | WO | disclosed |
| WO-2020245210-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020245210-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-12-10 | — | — | WO | disclosed |
| WO-2015004212-A1 | INHIBITOR OF NEUROPILIN AND USE THEREOF FOR THE TREATMENT OF NEUROPILIN-RELATED DISEASES | TRAGEX PHARMA (FR) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015004212-A1 | INHIBITOR OF NEUROPILIN AND USE THEREOF FOR THE TREATMENT OF NEUROPILIN-RELATED DISEASES | TRAGEX PHARMA (FR) | 2015-01-15 | — | — | WO | disclosed |
| EP-2823816-A1 | Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases | Tragex Pharma (FR) | 2015-01-14 | — | — | EP | disclosed |
| EP-2823816-A1 | Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases | Tragex Pharma (FR) | 2015-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | NRP1, PGR, TNFRSF1A | MAPT 4470/4885MEN1 4440/4885KMT2A 2944/4885 |
| US-20220307021-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | NRP1, MAPK1, MAPKAP1 | MAPT 2086/4885MEN1 4086/4885KMT2A 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.